Quectel BG770A-SN Combines 5G and NTN Support in Ultra-compact New Module
Quectel Wireless Solutions, a global IoT solutions provider, is pleased to announce the launch of the Quectel BG770A-SN ultra-compact 5G-ready satellite communication module. Compliant with 3GPP Releases 13, 14 and 17, the module supports the LTE NB1 and NB2 bands as well as non-terrestrial networks (NTN) over narrowband-IoT (NB-IoT). Ultra-low power consumption helps minimize energy usage and is achieved through enabling Power Saving Mode (PSM) and extended idle mode Discontinuous Reception (e-I-DRX).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241008708578/en/
Quectel BG770A-SN combines 5G and NTN support in ultra-compact new module (Photo: Business Wire)
Ideal for a broad range of applications including transportation, energy, maritime, heavy industry and agricultural applications, the module is dual mode, supporting both NTN & TN and featuring GNSS for positioning functionality. The module also supports iSIM.
“We’re delighted to unveil the Quectel BG770A-SN ultra-compact 5G-ready satellite communication module,” said Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “This module meets the needs of size-constrained, global use cases that demand the comprehensive coverage that satellite connectivity provides. Combining those attributes with low power consumption and robust security makes the module applicable to a wide range of use cases from POS to trackers and wearables. We’re proud to have combined cutting edge 5G and NTN capability in such a powerful, yet ultra-compact module.”
With the highly compact SMT form factor of 14.9mm x 12.9mm x 1.9mm, the Quectel BG770A-SN is ideally suited for use cases such as wireless point of sale devices (POS), smart metering, tracking and wearable devices. Designed for use in global markets, the module offers worldwide coverage utilizing the GEO satellite constellation. In addition, the module offers the Integrated Security Elements (ISE) feature which supports comprehensive security. Robustness is assured with module operating in an extended temperature range from -40°C to +85 °C.
Further benefits include the BG770A-SN’s super-slim profile in an LGA package and its rich set of interfaces. The module also supports download of firmware over the air (DFOTA) and offers rapid time to market thanks to a wide library of reference designs, evaluation tools and Quectel’s timely technical support. Combined, these help to minimize time and effort spent on device design and development.
In addition, the YECN028AA antenna is dedicated antenna, developed specifically for the BG770A-SN and is an external 5G/NTN antenna that covers 5G NR Sub-6GHz frequency bands, compatible with 4G/3G/2G/LPWA bands and NTN bands. With its high efficiency and gain, this omni-directional antenna provides an ideal solution for ensuring reliable high-speed data transmission.
Quectel will be exhibiting at MWC Las Vegas – schedule a meeting to find out more about the BG770A-SN and the rest of the Quectel range.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services.
Our growing global team of 5,600 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241008708578/en/
Contacts
Media contact: media@quectel.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PQE Group Joins Project-COMFORT to Advance Patient-Centric Blood Collection and Diagnostics30.12.2024 08:50:00 EET | Press release
PQE Group, a global consulting firm specializing in Life Sciences, is proud to contribute its expertise as a strategic partner in the Project-COMFORT consortium. This innovative public-private partnership, funded by Horizon Europe and supported by the Innovative Health Initiative Joint Undertaking (IHI JU), officially launched in November 2024, marking a transformative shift in blood collection and diagnostics. The ambitious 42-month project brings together 51 organizations from a broad spectrum of sectors, including academia, research institutions, hospitals, foundations, SMEs, medical technology, and pharmaceutical companies, all united by the mission to simplify, reduce the invasiveness of, and increase accessibility to blood collection through cutting-edge, patient-centered microsampling technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241229266268/en/ Follow Project-Comfort LinkedIn Page: https://www.linkedin.
Medical-Fish-Skin Company Kerecis Expands Silicone Fish-Skin Combination Product Range for Surgical and Trauma Wound with SurgiClose® Silicone27.12.2024 21:00:00 EET | Press release
Kerecis, the company pioneering the use of sustainably sourced fish skin and fatty acids in cellular therapy and tissue regeneration and protection, today announced the availability of SurgiClose® Silicone, which combines a fish-skin graft and silicone backing for efficient treatment of surgical and trauma wounds. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241227975454/en/ SurgiClose® Silicone (Photo: Business Wire) SurgiClose® Silicone is a part of the SurgiClose® product family, which is intact fish-skin intended for the management of trauma wounds and surgical wounds in the operating room. The new product is available in two variations, SurgiClose® Silicone Adhesive with borders that overlap the fish-skin underneath and SurgiClose® Silicone Standard with non-overlapping borders. “Applying Kerecis fish-skin to a surgical or trauma wound is a multi-step process that often requires supporting products such as sutures, st
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy27.12.2024 13:00:00 EET | Press release
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1 (≥1). “Today’s FDA approval of TEVIMBRA for the treatment of gastric or gastroesophageal junction cancers in PD-L1 positive adult patients marks a significant step forward in our mission to deliver transformative therapies to patients with cancer,” said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeiGene. “This is the second U.S. approval for TEVIMBRA this year, underscoring its potential to address critical needs in oncology. We remain deeply grateful to the patients, clinicians, and resear
Takeda Announces Approval of HYQVIA ® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia27.12.2024 08:00:00 EET | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] in patients with agammaglobulinemia or hypogammaglobulinemia1, disorders characterized by very low or absent levels of antibodies and an increased risk of serious recurring infection caused by primary immunodeficiency (PID) or secondary immunodeficiency (SID)2. The approval marks availability of the first and only facilitated subcutaneous immunoglobulin (fSCIG) therapy as a treatment option for appropriate patients in Japan. HYQVIA is the first plasma-derived therapy for subcutaneous injection in Japan that consists of a combination of one vial of Immunoglobulin 10% and one vial of Recombinant Human Hyaluronidase PH20 (rHuPH20). The administration of rHuPH20 increases the dispersion and absorption of immunoglobulin (IG) in the subcutaneous tissue, allowing larger volumes to be infu
Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 16:00:00 EET | Press release
Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 100 points. TIME and Statista analyzed 3,000 major companies from 150 countries, focusing exclusively on those with trans
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom